Drugs / MBX 1416
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06036784 | Sep 2023 → Nov 2024 | postgastrectomy syndrome | MBX Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07029412 | Aug 2025 → Apr 2026 | postgastrectomy syndrome | MBX Biosciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBX 1416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06036784 ↗ |
| Known as | imapextide | “MBX 1416 (INN imapextide)” NCT07029412 ↗ |
| Route | Subcutaneous | “Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg” NCT06036784 ↗ |